IP Library Granted Patent US 8,148,363
Granted Patent B2
US 8,148,363 · App. 12/993,607 · Granted Apr 3, 2012

Heterocyclic compounds as factor IXA inhibitors

Assignee: Schering Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,148,363
App. No.
12/993,607
Granted
Apr 3, 2012
Kind
B2
Abstract

The present invention relates to novel heterocyclic compounds of Formulae I-III; as disclosed herein or a pharmaceutically acceptable salt, solvate, ester, prodrug or stereoisomer thereof. Also disclosed are pharmaceutical compositions comprising said compounds, and methods for using said compounds for treating or preventing a thromboembolic disorder.

Claims (9)

1. A compound of formula IA or IB

or a pharmaceutically acceptable salt, or ester thereof; wherein each R 7 is independently selected from the group consisting of hydrogen, halo, alkyl, aminoalkyl, hydroxyalkyl, haloalkyl, alkoxy, -alkyl-O-hydroxyalkyl, haloalkoxy, cyano, hydroxy, —C(O)NR 5 R 6 , —C(═NOR 5 )N(R 6 ) 2 , ——C(O)OR 4 , -alkyl-NR 5 C(═O)OR 4 , -alkyl-S(═O ) 2 -aryl, -alkyl-NR 5 S(═O ) 2 -alkyl, —alkyl-NR 5 C(═0)NR 5 -alkyl, -alkyl-heteraryl, -alkyl-heterocyclyl, -alkyl-NR 5 C(═O )alkyl, -alkyl -NR 5 C(═O )aryl, alkoxyalkyl, aryl, heteroaryl, cycloalkyl, heterocycylyl, —NR 5 R 6 , —SR 4 , and —C(O )NR 5 R 6 ,

each R independently is H, alkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, or -(CR 5 R 6 ) n W, wherein W is selected from the group consisting of cycloalkyl, heterocyclyl,aryl, heteroaryl, —C(═O)NR 5 R 6 , C(═O)OR 4 , —OR 4 , —NR 5 R 6 ;

each R 4 independently is selected from the group consisting of H, alkyl, —C(═O)-heterocyclyl, —C(═O)NHalkyl, and —C(═O )N(alkyl) 2 ;

each R 5 and R 6 is independently selected from the group consisting of H alkyl, —C(═O)alkyl, and —C(═O)Oalkyl.

2. The compound of claim 1 selected from the group consisting of:

or a pharmaceutically acceptable salt, or ester thereof, wherein Bn=benzyl.

3. A pharmaceutical composition comprising at least one compound of claim 1 , or a pharmaceutically acceptable salt, or ester thereof and at least one pharmaceutically acceptable carrier.

4. A method of treating blood coagulation, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt, solvate, or ester thereof.

Assignments (4)
MERGER Recorded Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →
CHANGE OF NAME Recorded Aug 30, 2012
From: SCHERING CORPORATION
To: MERCK SHARP & DOHME CORP.
Reel/Frame 028884/0151 →
CHANGE OF NAME Recorded May 26, 2011
From: SCHERING CORPORATION
To: MERCK SHARP & DOHME CORP.
Reel/Frame 026349/0136 →
CHANGE OF NAME Recorded Dec 15, 2010
From: CLASBY, MARTIN C.; GREENLEE, WILLIAM; XIA, YAN; CHAN, TIN-YAU; CHELLIAH, MARIAPPAN V.; CHACKALAMANNIL, SAMUEL; PU, HAIYAN; EAGEN, KEITH A.; VACCARO, HENRY; MCKITTRICK, BRIAN A.; WANG, LIYUAN; GAO, XIAOBANG
To: SCHERING CORPORATION
Reel/Frame 025502/0456 →
Continuity (2)
Provisional Application 61054310 · May 19, 2008
Related Publication 20110065682A1 · Mar 17, 2011